Our data show that GNAS and KRAS mutations (18.8% and 10.4%) can already be found in the cfDNA of IPMN patients in general, concluding that IPMNs, as preneoplastic disease, can shed mutated KRAS and GNAS cfDNA into the bloodstream. Here, KRAS is linked to pancreatic intraductal papillary-mucinous neoplasm.